drugset
drugset / Trial / NCT05117346

An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia

NCT05117346 ↗

Phase 1/2 Completed 20 enrolled Cardix Therapeutics LLC
NaSequentialOpen-labelTreatment

Summary

The treatment of chronic bradycardia, one of the cardiovascular diseases, remains an essential unsolved issue. The objective of this project is to speed up a new drug CARDIX-101 clinical Phase 1IA trial for the treatment of chronic bradycardia and to solve an unmet medical need. To date, there is no regulatory approved drug of this type available in the U.S or the world. If the new drug CARDIX-101 demonstrated a significant positive effect on chronic bradycardia, it should have a sizeable demand and solve an unmet medical need.

Timeline

Start
2022-12-01
Primary completion
2024-06-30
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CARDIX-101 Unknown — Oral

Indications

No indication recorded.